Table 1.
Clinical and pathological characteristics of the WGS study cohort
| Sample | Age | PSA | Prior RT | cT | Bx GG | Staging | RP GG | pT | Vol (cc) |
|---|---|---|---|---|---|---|---|---|---|
| 11193_2 | 70 | 26.9 | y | cT1c | 5 |
MRI WBBS |
5 | pT3b | 21.3 |
| 11196_3 | 57 | 9.3 | y | cT1c | 3 |
MRI WBBS |
3 | pT3b | 2.1 |
| 11201_4 | 64 | 8.1 | n | cT3a | 5 |
CT WBBS |
5 | pT3b | 18.5 |
| 11199_5 | 67 | 7.8 | n | cT2a | 2 | MRI | 3 | pT3a | 15.2 |
| 11219_6 | 58 | 6.5 | n | cT1c | 2 | MRI | 2 | pT3a | 2.1 |
| 11231_9 | 59 | 6.1 | n | cT1c | 2 | MRI | 2 | pT2c | 3.7 |
| 11242_10 | 61 | 4.1 | n | cT2a | 2 |
CT WBBS |
2 | pT3a | 3.7 |
| 11243_11 | 76 | 7.9 | n | cT2a | 5 |
CT WBBS |
3 | pT3a | 7.5 |
PSA prostate-specific antigen, RT radiotherapy, cT clinical stage, Bx diagnostic biopsy, GG International Society of Urological Pathology Grade Group, RP radical prostatectomy, pT pathological stage, Vol (cc) tumour volume (cm3)